ATE240734T1 - Zubereitung von xanthinderivaten als feste dispersion - Google Patents

Zubereitung von xanthinderivaten als feste dispersion

Info

Publication number
ATE240734T1
ATE240734T1 AT96916342T AT96916342T ATE240734T1 AT E240734 T1 ATE240734 T1 AT E240734T1 AT 96916342 T AT96916342 T AT 96916342T AT 96916342 T AT96916342 T AT 96916342T AT E240734 T1 ATE240734 T1 AT E240734T1
Authority
AT
Austria
Prior art keywords
solid dispersion
preparation
xanthinderivates
hxdrogen
hxdroxy
Prior art date
Application number
AT96916342T
Other languages
English (en)
Inventor
Makoto Kigoshi
Tomoaki Masada
Yasuhiko Ueno
Yasuhiro Ishikawa
Eiji Hayakawa
Original Assignee
Kyowa Hakko Kogyo Kk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyowa Hakko Kogyo Kk filed Critical Kyowa Hakko Kogyo Kk
Application granted granted Critical
Publication of ATE240734T1 publication Critical patent/ATE240734T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems
    • C07D473/02Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems
    • C07D473/02Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT96916342T 1995-07-26 1996-06-07 Zubereitung von xanthinderivaten als feste dispersion ATE240734T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP19005895 1995-07-26
PCT/JP1996/001555 WO1997004782A1 (en) 1995-07-26 1996-06-07 Solid dispersion or solid dispersion preparation of xanthine derivatives

Publications (1)

Publication Number Publication Date
ATE240734T1 true ATE240734T1 (de) 2003-06-15

Family

ID=16251650

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96916342T ATE240734T1 (de) 1995-07-26 1996-06-07 Zubereitung von xanthinderivaten als feste dispersion

Country Status (9)

Country Link
US (1) US6254889B1 (de)
EP (1) EP0784974B1 (de)
JP (1) JP3938938B2 (de)
AT (1) ATE240734T1 (de)
DE (1) DE69628276T2 (de)
DK (1) DK0784974T3 (de)
ES (1) ES2199289T3 (de)
PT (1) PT784974E (de)
WO (1) WO1997004782A1 (de)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69837903T2 (de) * 1997-08-11 2008-02-14 Pfizer Products Inc., Groton Feste pharmazeutische Dispersionen mit erhöhter Bioverfügbarkeit
US6350786B1 (en) * 1998-09-22 2002-02-26 Hoffmann-La Roche Inc. Stable complexes of poorly soluble compounds in ionic polymers
US6706283B1 (en) * 1999-02-10 2004-03-16 Pfizer Inc Controlled release by extrusion of solid amorphous dispersions of drugs
DE60039379D1 (de) 1999-02-10 2008-08-21 Pfizer Prod Inc Pharmazeutische feste Dispersionen
BR0016555A (pt) 1999-12-23 2002-09-17 Pfizer Prod Inc Composições farmacêuticas que proporcionam concentrações acrescidas de droga
EP2415462A1 (de) 1999-12-23 2012-02-08 Mayne Pharma International Pty Ltd. Verbesserte pharmazeutische Zusammensetzungen für schwerlösliche Arzneistoffe
AR028253A1 (es) * 2000-03-16 2003-04-30 Pfizer Prod Inc Inhibidores de la glucogeno fosforilasa
US7125565B2 (en) * 2000-12-01 2006-10-24 Kyowa Hakko Kogyo Co., Ltd. Composition improved in the solubility or oral absorbability
US20030082231A1 (en) * 2001-02-02 2003-05-01 Cheryl Kos Coating for orally administered compositions
JP4310605B2 (ja) * 2001-05-25 2009-08-12 大塚製薬株式会社 医薬用組成物
ES2333645T3 (es) * 2001-06-22 2010-02-25 Bend Research, Inc. Composiciones farmaceuticas de dispersiones de medicamentos y polimeros neutros.
JP2005523262A (ja) * 2002-02-01 2005-08-04 ファイザー・プロダクツ・インク 薬物及び親油性ミクロ相形成物質の非晶質分散物の医薬組成物
EP1479300B1 (de) * 2002-02-22 2009-10-21 Ajinomoto Co., Inc. Aminosäurepulver und verfahren zu seiner herstellung
US20040229901A1 (en) * 2003-02-24 2004-11-18 Lauren Otsuki Method of treatment of disease using an adenosine A1 receptor antagonist
US20060293312A1 (en) * 2003-04-25 2006-12-28 Howard Dittrich Method of improved diuresis in individuals with impaired renal function
EP1620107A1 (de) * 2003-04-25 2006-02-01 Novacardia, Inc. Methode zur verbesserung der diurese bei patienten mit eingeschränkter nierenfunktion
EP1932529A1 (de) 2003-04-25 2008-06-18 Novacardia, Inc. Verfahren zur verbesserten Harnausscheidung bei Personen mit beeinträchtiger Nierenfunktion
KR20110128216A (ko) * 2003-05-09 2011-11-28 교와 핫꼬 기린 가부시키가이샤 미세 결정
ATE540671T1 (de) * 2003-08-04 2012-01-15 Bend Res Inc Pharmazeutische zusammensetzungen von adsorbaten von amorphen arzneimitteln und lipophilen mikrophasen-bildenden materialien
US20050239759A1 (en) * 2004-04-16 2005-10-27 Lauren Otsuki Method of treatment of disease using an adenosine A1 receptor antagonist and an aldosterone inhibitor
US20080312587A1 (en) * 2005-06-10 2008-12-18 Gruenethal Gmbh System for the Oral Administration of Solids to Persons Suffering from Dementia
EP1961422A1 (de) 2005-12-14 2008-08-27 Kyowa Hakko Kogyo Co., Ltd. Einfach absorbiertes orales präparat mit einem xanthin-derivat
JP2007308480A (ja) * 2006-04-20 2007-11-29 Shin Etsu Chem Co Ltd 腸溶性固体分散体を含んでなる固形製剤
JP2009540003A (ja) * 2006-06-16 2009-11-19 ノヴァカーディア,インク. Aa1raの低頻度投与を含む腎機能の長期間にわたる改善
WO2008121882A1 (en) * 2007-03-29 2008-10-09 Novacardia, Inc. Improved methods of administration of adenosine a1 receptor antagonists
WO2008121893A1 (en) * 2007-03-29 2008-10-09 Novacardia, Inc. Methods of treating heart failure and renal dysfunction in individuals with an adenosine a1 receptor antagonist
GB0708258D0 (en) * 2007-04-27 2007-06-06 Katholleke Universiteit Leuven New anti-viral nulceoside analogs
WO2008135828A2 (en) 2007-05-03 2008-11-13 Pfizer Products Inc. Nanoparticles comprising a drug, ethylcellulose, and a bile salt
WO2008135855A2 (en) 2007-05-03 2008-11-13 Pfizer Products Inc. Nanoparticles comprising a cholesteryl ester transfer protein inhibitor and a nonionizable polymer
WO2008149192A2 (en) 2007-06-04 2008-12-11 Pfizer Products Inc. Nanoparticles comprising a non-ionizable cellulosic polymer and an amphiphilic non-ionizable block copolymer
WO2008149230A2 (en) 2007-06-04 2008-12-11 Pfizer Products Inc. Nanoparticles comprising drug, a non-ionizable cellulosic polymer and tocopheryl polyethylene glycol succinate
HRP20191104T1 (hr) * 2007-09-25 2019-09-20 Solubest Ltd. Pripravci koji sadrže lipofilne aktivne spojeve i postupak za njihovu pripremu
US9724362B2 (en) 2007-12-06 2017-08-08 Bend Research, Inc. Pharmaceutical compositions comprising nanoparticles and a resuspending material
EP2240162A4 (de) 2007-12-06 2013-10-09 Bend Res Inc Nanoteilchen mit einem nicht-ionisierbaren polymer und einem amin-funktionalisierten methacrylat-copolymer
WO2009114601A2 (en) * 2008-03-11 2009-09-17 Dr. Reddy's Laboratories Ltd. Preparation of lenalidomide
KR20210043721A (ko) 2012-06-21 2021-04-21 메인 파마 인터내셔널 프로프라이어터리 리미티드 이트라코나졸 조성물 및 투여형, 그리고 이것들의 사용 방법
TWI615157B (zh) * 2013-02-06 2018-02-21 大塚製藥股份有限公司 包括不定形西洛他唑的固體分散劑
AR106018A1 (es) 2015-08-26 2017-12-06 Achillion Pharmaceuticals Inc Compuestos de arilo, heteroarilo y heterocíclicos para el tratamiento de trastornos médicos
ES2908479T3 (es) 2015-08-26 2022-04-29 Achillion Pharmaceuticals Inc Compuestos para el tratamiento de trastornos inmunitarios e inflamatorios
EP3939591A1 (de) 2016-06-27 2022-01-19 Achillion Pharmaceuticals, Inc. Chinazolin- und indolverbindungen zur behandlung von medizinischen leiden
AU2018227849B2 (en) 2017-03-01 2022-04-28 Achillion Pharmaceuticals, Inc. Aryl, heteroaryl, and heterocyclic pharmaceutical compounds for treatment of medical disorders
TWI780270B (zh) 2017-11-28 2022-10-11 靜岡縣公立大學法人 固體分散體
JP7538113B2 (ja) 2018-08-20 2024-08-21 アキリオン ファーマシューティカルズ,インコーポレーテッド 補体d因子の医学的障害の治療のための医薬化合物
WO2020051532A2 (en) 2018-09-06 2020-03-12 Achillion Pharmaceuticals, Inc. Macrocyclic compounds for the treatment of medical disorders
WO2020081723A1 (en) 2018-10-16 2020-04-23 Georgia State University Research Foundation, Inc. Carbon monoxide prodrugs for the treatment of medical disorders
US20230105108A1 (en) 2019-12-19 2023-04-06 Georgia State University Research Foundation, Inc. Compounds for the treatment of bacterial infections and potentiation of antibiotics
CN115362162A (zh) 2020-02-20 2022-11-18 艾其林医药公司 用于治疗补体因子d介导的障碍的杂芳基化合物
JP7787164B2 (ja) 2020-09-23 2025-12-16 アキリオン ファーマシューティカルズ, インコーポレーテッド 補体媒介性障害の治療のための医薬化合物

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3976071A (en) * 1974-01-07 1976-08-24 Dynatech Corporation Methods of improving control of release rates and products useful in same
US5286489A (en) * 1985-08-26 1994-02-15 The Procter & Gamble Company Taste masking compositions
CH674148A5 (de) * 1986-06-24 1990-05-15 Racz Istvan
JP2521461B2 (ja) 1987-03-10 1996-08-07 エスエス製薬株式会社 持続性錠剤
ES2077023T3 (es) * 1989-03-10 1995-11-16 Yamanouchi Pharma Co Ltd Material de recubrimiento que controla la liberacion de un medicamento para formulaciones de actividad prolongada.
US5290782A (en) 1989-09-01 1994-03-01 Kyowa Hakko Kogyo Co., Ltd. Xanthine derivatives
JPH06102662B2 (ja) * 1989-09-01 1994-12-14 協和醗酵工業株式会社 キサンチン誘導体
EP0580860B2 (de) * 1991-04-16 2004-12-15 Nippon Shinyaku Company, Limited Verfahren zur herstellung einer festen dispersion

Also Published As

Publication number Publication date
US6254889B1 (en) 2001-07-03
DE69628276D1 (de) 2003-06-26
DE69628276T2 (de) 2004-04-08
DK0784974T3 (da) 2003-09-01
PT784974E (pt) 2003-09-30
EP0784974A1 (de) 1997-07-23
EP0784974A4 (de) 2000-09-27
JP3938938B2 (ja) 2007-06-27
EP0784974B1 (de) 2003-05-21
ES2199289T3 (es) 2004-02-16
WO1997004782A1 (en) 1997-02-13

Similar Documents

Publication Publication Date Title
ATE240734T1 (de) Zubereitung von xanthinderivaten als feste dispersion
PT705833E (pt) Derivado de dc-89
DE69628804D1 (de) Substitutierte heterozyclische Derivate als CRF Antagonisten
EP0731106A4 (de) Neue peptid-derivate
AU9281198A (en) Benzofuran derivatives
DK0695755T3 (da) Pyrrolocarbazoler
EP0632038A4 (de) Methotrexat-derivate.
DK0958821T3 (da) Fedtemulsion, der indeholder xanthinderivat
ID25477A (id) Turunan-turunan spiropiperidin
EP0676399A4 (de) Methotrexat-derivate.
EP0555479A4 (de)
ES2149180T3 (es) Derivado de pirazolotiazolopirimidina.
EP0994111A4 (de) Tetrahydrofuranderivate

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0784974

Country of ref document: EP

EEFA Change of the company name
REN Ceased due to non-payment of the annual fee